Alzamend Neuro (NASDAQ:ALZN) Price Target Raised to $26.00

Alzamend Neuro (NASDAQ:ALZN) had its price target increased by equities researchers at Ascendiant Capital Markets from $25.00 to $26.00 in a research note issued on Wednesday,Benzinga reports. The firm currently has a “buy” rating on the stock.

Separately, Weiss Ratings cut shares of Alzamend Neuro from a “sell (e+)” rating to a “sell (e)” rating in a research report on Monday. One analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $26.00.

Alzamend Neuro Price Performance

Shares of NASDAQ:ALZN opened at $1.52 on Wednesday. The firm has a market capitalization of $7.28 million, a PE ratio of -0.52 and a beta of 0.16. The business has a 50-day moving average of $1.29 and a two-hundred day moving average of $1.40. Alzamend Neuro has a 12 month low of $0.84 and a 12 month high of $2.68.

Alzamend Neuro (NASDAQ:ALZN) last released its quarterly earnings data on Wednesday, July 22nd. The company reported ($0.74) earnings per share for the quarter, missing the consensus estimate of ($0.67) by ($0.07). As a group, research analysts anticipate that Alzamend Neuro will post -2.6 earnings per share for the current year.

Institutional Investors Weigh In On Alzamend Neuro

An institutional investor recently raised its position in Alzamend Neuro stock. DRW Securities LLC increased its stake in Alzamend Neuro, Inc. (NASDAQ:ALZN) by 27.5% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 116,319 shares of the company’s stock after buying an additional 25,074 shares during the quarter. DRW Securities LLC owned about 3.06% of Alzamend Neuro worth $212,000 as of its most recent filing with the SEC. Hedge funds and other institutional investors own 49.61% of the company’s stock.

Alzamend Neuro Company Profile

Alzamend Neuro, Inc, an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease.